The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Value Is Expected For The Scleroderma Diagnostics And Therapeutics Market At The End Of The 2026–2030 Forecast Period?
The scleroderma diagnostics and therapeutics market has demonstrated substantial growth in recent years. It is projected to expand from $2.94 billion in 2025 to $3.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.6%. The historical growth can be attributed to several factors including limited awareness of scleroderma, a lack of targeted therapies, the prevalence of conventional diagnostic methods, low early diagnosis rates, and regional healthcare disparities.
The market for scleroderma diagnostics and therapeutics is projected to experience substantial expansion over the coming years. By 2030, its valuation is anticipated to reach $4.39 billion, expanding at a compound annual growth rate (CAGR) of 8.3%. This projected growth is largely driven by factors such as the advancement of targeted biologics, the emergence of AI-powered diagnostics, the increasing number of rare disease centers, wider adoption of telemedicine, and enhanced patient advocacy alongside rising awareness. Key trends expected during this forecast timeframe encompass the embrace of early diagnosis, the introduction of novel biologic therapies, a preference for minimally invasive treatments, the incorporation of AI within diagnostics, and the use of telehealth specifically for rare diseases.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23509&type=smp
Which Market Drivers Are Supporting The Expansion Of The Scleroderma Diagnostics And Therapeutics Market?
The increasing incidence of autoimmune conditions is anticipated to fuel the expansion of the scleroderma diagnostics and therapeutics market in the future. These are ailments characterized by the immune system erroneously targeting healthy cells within the body. The growing occurrence of autoimmune diseases can be attributed to genetic factors, given that particular gene variations impact immune system function and lead to irregularities in connective tissues. Scleroderma diagnostics and therapeutics enhance the management of autoimmune diseases through early identification and tailored treatment plans, which simplify clinical decisions and ultimately lead to better patient results and an improved quality of life. For example, data from the Australian Institute of Health and Welfare, an Australian government body, revealed in June 2024 that 514,000 (2.0%) individuals had rheumatoid arthritis in 2022. This contributed to 2.0% of the overall disease burden and 16% of the burden of musculoskeletal conditions in 2023. Additionally, 1,322 deaths (5.1 deaths per 100,000 population) were documented in 2022, representing 0.7% of all fatalities. Consequently, the increasing incidence of autoimmune diseases is a key factor propelling the expansion of the scleroderma diagnostics and therapeutics market.
What Segment Types Make Up The Scleroderma Diagnostics And Therapeutics Market?
The scleroderma diagnostics and therapeutics market covered in this report is segmented –
1) By Drug Type: Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Antagonists, Calcium Channel Blockers, Phosphodiesterase Type 5 (PDE-5) Inhibitors, Chelating Agents, Prostacyclin Analogues, Other Drug Types
2) By Diagnostic Test Type: Blood Tests, Imaging Techniques, Skin Biopsy, Pulmonary Function Tests, Electrocardiogram And Echocardiogram
3) By Indication: Systemic Scleroderma, Localized Scleroderma
4) By Route Of Administration: Oral, Injectable, Topical
5) By End-User: Hospitals, Diagnostic Centers, Private Laboratories, Government Laboratories, Other End-Users
Subsegments:
1) By Corticosteroids: Prednisone, Methylprednisolone, Dexamethasone
2) By Immunosuppressive Agents: Methotrexate, Mycophenolate Mofetil, Azathioprine, Cyclophosphamide
3) By Endothelin Receptor Antagonists: Bosentan, Ambrisentan, Macitentan
4) By Calcium Channel Blockers: Nifedipine, Amlodipine, Diltiazem
5) By Phosphodiesterase Type 5 Inhibitors (Pde-5) Inhibitors: Sildenafil, Tadalafil, Vardenafil
6) By Chelating Agents: D-Penicillamine, Deferoxamine
7) By Prostacyclin Analogues: Epoprostenol, Iloprost, Treprostinil
8) By Other Drug Types: Rituximab (Monoclonal Antibody), Abatacept (T-Cell Modulator), Tocilizumab (Il-6 Inhibitor)
What Trends Are Projected To Affect The Scleroderma Diagnostics And Therapeutics Market?
Companies active in the scleroderma diagnostics and therapeutics market are prioritizing the development of advanced diagnostic techniques, including fully human CD19 CAR T-cell therapy, aimed at improving disease management and patient outcomes. This therapy is a form of immunotherapy where a patient’s own T cells (a type of immune cell) are genetically engineered to express a chimeric antigen receptor (CAR) that specifically targets CD19, a protein located on the surface of B cells. Notably, in October 2023, US-based biopharmaceutical company Kyverna Therapeutics Inc. secured FDA clearance for its Investigational New Drug (IND) application for KYV-101, a fully human CD19 CAR T-cell therapy, enabling the commencement of a Phase 1/2 clinical trial for diffuse cutaneous systemic sclerosis (scleroderma) treatment. The forthcoming KYSA-5 trial is set to evaluate the safety and efficacy of KYV-101, a therapy designed to specifically target B cells implicated in the progression of autoimmune diseases. Its ultimate goal is to reset the immune system and improve outcomes for scleroderma patients.
Who Are The Key Players Driving Competition In The Scleroderma Diagnostics And Therapeutics Market?
Major companies operating in the scleroderma diagnostics and therapeutics market are Johnson and Johnson, F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Bayer AG, Sanofi S.A., GSK plc, Boehringer Ingelheim International GmbH, Galapagos NV, Inventiva S.A., Redx Pharma plc, Kadmon Holdings Inc., Certa Therapeutics Pty Ltd, Corbus Pharmaceuticals Holdings Inc., aTyr Pharma Inc., MediciNova Inc., Pfizer Inc., Novartis AG, Abbvie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly And Company, Amgen Inc., UCB Pharma, CSL Behring, Mitsubishi Tanabe Pharma, Chugai Pharmaceutical Co. Ltd., Kyowa Kirin
Read the full scleroderma diagnostics and therapeutics market report here:
How Is The Scleroderma Diagnostics And Therapeutics Market Distributed Across Key Geographic Regions?
North America was the largest region in the scleroderma diagnostics and therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the scleroderma diagnostics and therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Scleroderma Diagnostics And Therapeutics Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=23509&type=smp
Browse Through More Reports Similar to the Global Scleroderma Diagnostics And Therapeutics Market 2026, By The Business Research Company
Psoriasis Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/psoriasis-drugs-global-market-report
Dermatitis Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/dermatitis-drugs-global-market-report
Seborrheic Dermatitis Global Market Report
https://www.thebusinessresearchcompany.com/report/seborrheic-dermatitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model